Stem definition | Drug id | CAS RN |
---|---|---|
1230 | 54739-18-3 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 14.87 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 13.46 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 53 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 23.50 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 31.95 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.20 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 12.50 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 5, 1994 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 148.42 | 18.86 | 149 | 5371 | 202945 | 46477597 |
Suicide attempt | 103.17 | 18.86 | 70 | 5450 | 54966 | 46625576 |
Intentional self-injury | 93.31 | 18.86 | 49 | 5471 | 24117 | 46656425 |
Intentional overdose | 88.32 | 18.86 | 68 | 5452 | 64876 | 46615666 |
Toxicity to various agents | 72.60 | 18.86 | 106 | 5414 | 211660 | 46468882 |
Obsessive-compulsive disorder | 67.71 | 18.86 | 22 | 5498 | 3193 | 46677349 |
Serotonin syndrome | 65.83 | 18.86 | 39 | 5481 | 24181 | 46656361 |
Suicidal ideation | 55.57 | 18.86 | 49 | 5471 | 56333 | 46624209 |
Drug abuse | 54.45 | 18.86 | 51 | 5469 | 63357 | 46617185 |
Neuroleptic malignant syndrome | 52.96 | 18.86 | 26 | 5494 | 11096 | 46669446 |
Anxiety | 50.92 | 18.86 | 83 | 5437 | 181874 | 46498668 |
Somnolence | 43.22 | 18.86 | 71 | 5449 | 156450 | 46524092 |
Oscillopsia | 41.58 | 18.86 | 8 | 5512 | 130 | 46680412 |
Schizophrenia | 40.70 | 18.86 | 20 | 5500 | 8548 | 46671994 |
Completed suicide | 40.02 | 18.86 | 66 | 5454 | 145854 | 46534688 |
Mydriasis | 36.77 | 18.86 | 20 | 5500 | 10533 | 46670009 |
Electrocardiogram QT prolonged | 36.04 | 18.86 | 37 | 5483 | 51288 | 46629254 |
Drug level increased | 33.41 | 18.86 | 23 | 5497 | 18418 | 46662124 |
Torsade de pointes | 31.52 | 18.86 | 19 | 5501 | 12135 | 46668407 |
Depression | 30.37 | 18.86 | 64 | 5456 | 170040 | 46510502 |
Blood creatine phosphokinase increased | 29.11 | 18.86 | 25 | 5495 | 27699 | 46652843 |
Tremor | 28.62 | 18.86 | 50 | 5470 | 115589 | 46564953 |
Galactorrhoea | 27.89 | 18.86 | 12 | 5508 | 3785 | 46676757 |
Overdose | 27.75 | 18.86 | 46 | 5474 | 101933 | 46578609 |
Sopor | 27.42 | 18.86 | 21 | 5499 | 19807 | 46660735 |
Mental disorder | 27.24 | 18.86 | 22 | 5498 | 22403 | 46658139 |
Drug screen false positive | 26.88 | 18.86 | 8 | 5512 | 869 | 46679673 |
Personality disorder | 26.68 | 18.86 | 11 | 5509 | 3122 | 46677420 |
Delirium | 26.42 | 18.86 | 27 | 5493 | 37201 | 46643341 |
Activation syndrome | 26.26 | 18.86 | 6 | 5514 | 230 | 46680312 |
Depersonalisation/derealisation disorder | 25.76 | 18.86 | 8 | 5512 | 1002 | 46679540 |
Restlessness | 24.75 | 18.86 | 22 | 5498 | 25502 | 46655040 |
Alice in wonderland syndrome | 23.50 | 18.86 | 4 | 5516 | 31 | 46680511 |
Dysarthria | 22.71 | 18.86 | 25 | 5495 | 37473 | 46643069 |
Depressed level of consciousness | 22.61 | 18.86 | 28 | 5492 | 47541 | 46633001 |
Agitation | 22.24 | 18.86 | 30 | 5490 | 55385 | 46625157 |
Akinesia | 21.23 | 18.86 | 8 | 5512 | 1793 | 46678749 |
Anaemia folate deficiency | 20.59 | 18.86 | 5 | 5515 | 250 | 46680292 |
Congestive cardiomyopathy | 20.38 | 18.86 | 11 | 5509 | 5702 | 46674840 |
Dysphoria | 19.69 | 18.86 | 10 | 5510 | 4579 | 46675963 |
Aspiration of gastric residual | 19.30 | 18.86 | 3 | 5517 | 12 | 46680530 |
Psychotic disorder | 19.01 | 18.86 | 18 | 5502 | 22603 | 46657939 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Loss of libido | 120.05 | 20.49 | 33 | 4714 | 2009 | 29945722 |
Apathy | 109.20 | 20.49 | 40 | 4707 | 6192 | 29941539 |
Drug interaction | 107.25 | 20.49 | 144 | 4603 | 199424 | 29748307 |
Schizophrenia | 104.85 | 20.49 | 43 | 4704 | 9005 | 29938726 |
Psychotic disorder | 98.85 | 20.49 | 54 | 4693 | 21461 | 29926270 |
Serotonin syndrome | 96.56 | 20.49 | 50 | 4697 | 17841 | 29929890 |
Neuroleptic malignant syndrome | 95.08 | 20.49 | 48 | 4699 | 16247 | 29931484 |
Suicidal ideation | 84.67 | 20.49 | 59 | 4688 | 36055 | 29911676 |
Obsessive-compulsive disorder | 66.72 | 20.49 | 25 | 4722 | 4116 | 29943615 |
Persecutory delusion | 53.86 | 20.49 | 18 | 4729 | 2122 | 29945609 |
Toxicity to various agents | 51.83 | 20.49 | 97 | 4650 | 177086 | 29770645 |
Depression | 50.95 | 20.49 | 67 | 4680 | 90370 | 29857361 |
Weight increased | 46.10 | 20.49 | 58 | 4689 | 74855 | 29872876 |
Intentional overdose | 42.60 | 20.49 | 42 | 4705 | 41439 | 29906292 |
Catatonia | 41.32 | 20.49 | 18 | 4729 | 4362 | 29943369 |
Anxiety | 40.75 | 20.49 | 60 | 4687 | 89811 | 29857920 |
Aggression | 39.07 | 20.49 | 38 | 4709 | 36869 | 29910862 |
Completed suicide | 38.88 | 20.49 | 62 | 4685 | 99430 | 29848301 |
Sopor | 38.14 | 20.49 | 23 | 4724 | 10968 | 29936763 |
Salivary hypersecretion | 34.73 | 20.49 | 19 | 4728 | 7547 | 29940184 |
Social avoidant behaviour | 34.48 | 20.49 | 14 | 4733 | 2849 | 29944882 |
Hanging | 34.32 | 20.49 | 7 | 4740 | 114 | 29947617 |
Agitation | 33.44 | 20.49 | 42 | 4705 | 54031 | 29893700 |
Suicide attempt | 31.94 | 20.49 | 34 | 4713 | 36663 | 29911068 |
Respiratory fatigue | 31.61 | 20.49 | 6 | 4741 | 66 | 29947665 |
Obsessive thoughts | 31.06 | 20.49 | 9 | 4738 | 662 | 29947069 |
Antipsychotic drug level above therapeutic | 30.95 | 20.49 | 10 | 4737 | 1060 | 29946671 |
Akathisia | 30.39 | 20.49 | 16 | 4731 | 5888 | 29941843 |
Cyclothymic disorder | 30.27 | 20.49 | 6 | 4741 | 84 | 29947647 |
Neonatal behavioural syndrome | 28.75 | 20.49 | 6 | 4741 | 110 | 29947621 |
Tic | 28.18 | 20.49 | 11 | 4736 | 2021 | 29945710 |
Encephalitis toxic | 27.84 | 20.49 | 6 | 4741 | 129 | 29947602 |
Sedation | 27.66 | 20.49 | 22 | 4725 | 16351 | 29931380 |
Tremor | 26.75 | 20.49 | 45 | 4702 | 75318 | 29872413 |
Heat stroke | 24.63 | 20.49 | 8 | 4739 | 862 | 29946869 |
Blood creatine phosphokinase increased | 23.88 | 20.49 | 32 | 4715 | 43816 | 29903915 |
Somnolence | 23.38 | 20.49 | 49 | 4698 | 96714 | 29851017 |
Drug withdrawal syndrome | 22.08 | 20.49 | 21 | 4726 | 19788 | 29927943 |
Impulsive behaviour | 21.59 | 20.49 | 9 | 4738 | 1956 | 29945775 |
Mental impairment | 21.33 | 20.49 | 15 | 4732 | 9262 | 29938469 |
Cerebellar atrophy | 20.87 | 20.49 | 6 | 4741 | 429 | 29947302 |
Inappropriate antidiuretic hormone secretion | 20.70 | 20.49 | 16 | 4731 | 11406 | 29936325 |
Source | Code | Description |
---|---|---|
ATC | N06AB08 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Selective serotonin reuptake inhibitors |
FDA MoA | N0000000109 | Serotonin Uptake Inhibitors |
FDA EPC | N0000175696 | Serotonin Reuptake Inhibitor |
CHEBI has role | CHEBI:35469 | thymoanaleptics |
CHEBI has role | CHEBI:35474 | minor tranquilisers |
CHEBI has role | CHEBI:50949 | serotonin reuptake inhibitor |
MeSH PA | D014151 | Anti-Anxiety Agents |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D018687 | Antidepressive Agents, Second-Generation |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D065609 | Cytochrome P-450 CYP1A2 Inhibitors |
MeSH PA | D065689 | Cytochrome P-450 CYP2C19 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D014179 | Neurotransmitter Uptake Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D018490 | Serotonin Agents |
MeSH PA | D017367 | Serotonin Uptake Inhibitors |
MeSH PA | D014149 | Tranquilizing Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Social phobia | indication | 25501002 | DOID:11257 |
Obsessive-compulsive disorder | indication | 191736004 | DOID:10933 |
Depressive disorder | off-label use | 35489007 | |
Posttraumatic stress disorder | off-label use | 47505003 | DOID:2055 |
Bipolar affective disorder, current episode depression | off-label use | 191627008 | DOID:3312 |
Suicidal thoughts | contraindication | 6471006 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
Upper gastrointestinal hemorrhage | contraindication | 37372002 | |
Syndrome of inappropriate vasopressin secretion | contraindication | 55004003 | DOID:3401 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Epilepsy | contraindication | 84757009 | DOID:1826 |
Hyponatremia | contraindication | 89627008 | |
Mania | contraindication | 231494001 | |
Hypomania | contraindication | 231496004 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Serotonin syndrome | contraindication | 371089000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Poor metabolizer due to cytochrome p450 CYP2D6 variant | contraindication | 423629005 | |
Smokes tobacco daily | contraindication | 449868002 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.36 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 8.51 | WOMBAT-PK | CHEMBL | |||
Sodium-dependent dopamine transporter | Transporter | Ki | 8.84 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.44 | CHEMBL | |||||
Cytochrome P450 1A2 | Enzyme | Ki | 5.07 | WOMBAT-PK | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.95 | PDSP | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.44 | CHEMBL | |||||
Sodium-dependent serotonin transporter | Transporter | INHIBITOR | Ki | 8.19 | IUPHAR |
ID | Source |
---|---|
4023976 | VUID |
N0000021981 | NUI |
D00824 | KEGG_DRUG |
61718-82-9 | SECONDARY_CAS_RN |
4020892 | VANDF |
4023976 | VANDF |
C0085228 | UMLSCUI |
CHEBI:5138 | CHEBI |
FVX | PDB_CHEM_ID |
CHEMBL814 | ChEMBL_ID |
CHEMBL1409 | ChEMBL_ID |
DB00176 | DRUGBANK_ID |
D016666 | MESH_DESCRIPTOR_UI |
9560989 | PUBCHEM_CID |
7189 | IUPHAR_LIGAND_ID |
3879 | INN_ID |
O4L1XPO44W | UNII |
203143 | RXNORM |
40916 | MMSL |
4758 | MMSL |
d03804 | MMSL |
003633 | NDDF |
003634 | NDDF |
116522003 | SNOMEDCT_US |
372905008 | SNOMEDCT_US |
96213009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2848 | CAPSULE, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 21 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0228-2849 | CAPSULE, EXTENDED RELEASE | 150 mg | ORAL | ANDA | 21 sections |
Fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1670 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 34 sections |
Fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1671 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 34 sections |
Fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0832-1672 | TABLET, FILM COATED | 100 mg | ORAL | ANDA | 34 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10370-175 | CAPSULE, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 30 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10370-176 | CAPSULE, EXTENDED RELEASE | 150 mg | ORAL | ANDA | 30 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-270 | TABLET | 25 mg | ORAL | NDA | 11 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-683 | TABLET, COATED | 50 mg | ORAL | NDA AUTHORIZED GENERIC | 31 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-0164 | TABLET | 25 mg | ORAL | ANDA | 32 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-0165 | TABLET | 50 mg | ORAL | ANDA | 32 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-0166 | TABLET | 100 mg | ORAL | ANDA | 32 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-158 | TABLET, COATED | 25 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-159 | TABLET, COATED | 50 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-160 | TABLET, COATED | 100 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8018 | TABLET, COATED | 25 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68071-2337 | TABLET, COATED | 50 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0637 | TABLET, COATED | 50 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68788-7219 | TABLET, COATED | 100 mg | ORAL | NDA authorized generic | 31 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69452-182 | CAPSULE, EXTENDED RELEASE | 100 mg | ORAL | ANDA | 22 sections |
Fluvoxamine Maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69452-183 | CAPSULE, EXTENDED RELEASE | 150 mg | ORAL | ANDA | 22 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1057 | TABLET, COATED | 100 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-1643 | TABLET, COATED | 50 mg | ORAL | NDA authorized generic | 31 sections |
fluvoxamine maleate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71335-0264 | TABLET, COATED | 100 mg | ORAL | NDA authorized generic | 31 sections |